相似文献
1
Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition.
Oncoimmunology. 2013 Sep 1;2(9):e25820. doi: 10.4161/onci.25820. Epub 2013 Jul 29.
2
3
Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Cell Immunol. 2006 Jan;239(1):22-30. doi: 10.1016/j.cellimm.2006.03.002. Epub 2006 Apr 21.
4
Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.
J Immunol. 2013 Apr 15;190(8):4408-19. doi: 10.4049/jimmunol.1202950. Epub 2013 Mar 18.
5
In vitro Natural Killer Cell Immunotherapy for Medulloblastoma.
Front Oncol. 2013 Apr 19;3:94. doi: 10.3389/fonc.2013.00094. eCollection 2013.
6
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.
7
Upregulated expression of NKG2D and its ligands give potential therapeutic targets for patients with thymoma.
Cancer Gene Ther. 2015 Jul;22(7):368-74. doi: 10.1038/cgt.2015.29. Epub 2015 Jun 26.
8
An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma.
Cancers (Basel). 2020 Nov 30;12(12):3583. doi: 10.3390/cancers12123583.
9
Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity.
Tumour Biol. 2016 Apr;37(4):5455-66. doi: 10.1007/s13277-015-4313-2. Epub 2015 Nov 13.
10
MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
J Immunother Cancer. 2019 Aug 6;7(1):207. doi: 10.1186/s40425-019-0687-9.
引用本文的文献
1
Harnessing NK Cells to Control Metastasis.
Vaccines (Basel). 2022 Nov 25;10(12):2018. doi: 10.3390/vaccines10122018.
2
NK Cell-Based Immunotherapy in Cancer Metastasis.
Cancers (Basel). 2018 Dec 28;11(1):29. doi: 10.3390/cancers11010029.
3
Translating epithelial mesenchymal transition markers into the clinic: Novel insights from proteomics.
EuPA Open Proteom. 2016 Jan 6;10:31-41. doi: 10.1016/j.euprot.2016.01.003. eCollection 2016 Mar.
4
Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors.
Oncoimmunology. 2015 Aug 12;5(2):e1074378. doi: 10.1080/2162402X.2015.1074378. eCollection 2016 Feb.
5
Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
J Gastroenterol. 2016 Dec;51(12):1101-1111. doi: 10.1007/s00535-016-1197-x. Epub 2016 Mar 22.
6
The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients.
Sci Rep. 2014 Aug 20;4:6138. doi: 10.1038/srep06138.
7
Molecular Bases for the Regulation of NKG2D Ligands in Cancer.
Front Immunol. 2014 Mar 21;5:106. doi: 10.3389/fimmu.2014.00106. eCollection 2014.
本文引用的文献
1
Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor.
J Immunol. 2013 Apr 15;190(8):4408-19. doi: 10.4049/jimmunol.1202950. Epub 2013 Mar 18.
2
HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer.
Oncogene. 2009 Jun 25;28(25):2370-82. doi: 10.1038/onc.2009.117. Epub 2009 May 11.
3
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
Nat Rev Cancer. 2009 Apr;9(4):265-73. doi: 10.1038/nrc2620. Epub 2009 Mar 5.
4
NKG2D ligands: key targets of the immune response.
Trends Immunol. 2008 Aug;29(8):397-403. doi: 10.1016/j.it.2008.04.007. Epub 2008 Jul 3.
5
The NKG2D receptor: sensing stressed cells.
Trends Mol Med. 2008 Apr;14(4):179-89. doi: 10.1016/j.molmed.2008.02.004. Epub 2008 Mar 18.
6
Transcriptional regulation of MICA and MICB: a novel polymorphism in MICB promoter alters transcriptional regulation by Sp1.
Eur J Immunol. 2007 Jul;37(7):1938-53. doi: 10.1002/eji.200737031.
7
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands.
Nature. 2007 May 24;447(7143):482-6. doi: 10.1038/nature05768. Epub 2007 May 9.
8
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.
Eur J Immunol. 2007 Mar;37(3):675-85. doi: 10.1002/eji.200636639.
9
Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor.
J Biol Chem. 2006 Oct 13;281(41):30419-30. doi: 10.1074/jbc.M604868200. Epub 2006 Aug 10.
10
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity.
J Exp Med. 2006 Feb 20;203(2):289-95. doi: 10.1084/jem.20051986. Epub 2006 Feb 6.
Zotero 插件